Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202958 | 0.99 | L3MBTL1 (0.44) | L3MBTL3L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL2201538 | 0.92 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1LMNATSHRHTT | |
| SCHEMBL2201524 | 0.92 | TSHR (0.46) | L3MBTL1ALDH1A1LMNATSHRHTT | |
| SCHEMBL2202061 | 0.91 | ALDH1A1 (0.43) | L3MBTL3L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL2201653 | 0.91 | KMT2A (0.41) | L3MBTL1ALDH1A1LMNATSHRHTT | |
| SCHEMBL2199954 | 0.89 | KMT2A (0.44) | L3MBTL3L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL2201156 | 0.89 | KMT2A (0.45) | L3MBTL3L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL2201297 | 0.87 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1TDP1MBTD1 | |
| SCHEMBL12429747 | 0.85 | CYP2C9 (0.42) | L3MBTL3L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL2200200 | 0.85 | TSHR (0.44) | L3MBTL3L3MBTL1ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | L3MBTL3 4146/4885L3MBTL1 4149/4885ALDH1A1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.